Search This Blog

Saturday, 6 April 2019

Tomorrow's medicines: key programme talks announced for EACPT Stockholm Congess 29 June - 2 July 2019

The next EACPT Congress will be held from 29th June to 2nd July in 2019 in Stockholm as a partnership between the EACPT and the Swedish Society for Pharmacology, Clinical Pharmacology and Therapeutics.



The Congress will address Tomorrow's Healthcare Challenges and will be held at the City Conference Centre - 5 minutes from Stockholm Central Station.
The Congress Reception on the evening of Saturday 29th June, will be held at Stockholm City Hall, the venue of the Nobel Prize banquet.

The Keynote Opening Lecture will be given by the President at the Karolinska Institute, Professor Ole Petter Ottersen, on global health and clinical pharmacology.
Professor Urs Meyer from Switzerland will give the 2019 EACPT Lifetime Achievement Award Lecture based on his work on individual variation in drug response.
Further awards will be presented, including Scientific Awards, including Young Investigator, and EACPT Education Awards.

Around 60 invited speakers are expected from throughout Europe and beyond. Congress keynote lectures will include:

Plenary lectures
Ylva Böttiger:  Clinical pharmacology reaching out - 25 years with EACPT
Ole Petter Ottersen:  Global health research and education in Europe - how can clinical pharmacology contribute?
Harry Sokol:  Gut microbiota - a new actor in pharmacology?
Urs Meyer:  Therapeutic Lessons from Human Individuality
Rosa Giuliani:  Update on treating breast cancer
Jenny Kindblom:  Pediatric clinical trials and their pitfalls 
Tim Nicholson:  New targets in psychopharmacology
Sylvie Laporte:  Meta-epidemiological studies to detect, quantify and adjust for bias in open-label trials
Stefan James:  Innovative ways of performing clinical trials
Björn Wettermark:  How to measure drug utilisation

Cardiovascular prevention
Stephane Laurent:  Update on treating hypertension
Gerard Rongen:  PCSK9 inhibitors - going lower but for whom and at what price? Paul Hjemdahl:  Dual or triple antithrombotic therapy - is two company and three a crowd?

An ageing population
Denis O'Mahoney:  STOPP/START decision support for elderly prescribing
Anne Spinewine:  Prescribing in the frail elderly
 
Workshops
Martin Henriksson:  How to perform a health economic study 
Olof Beck and Markus Meyer: How to measure drug exposure
Jan Marcusson:  How to make on oral presentation and feel good about it

Closing the money gap
Gerd Lärfars:  Horizon scanning frontiers
Andras Inotai:  How to solve money gap to ensure patient access to pharmaceuticals in EU counties
David Webb:  Health economics: big ideas from a small country

Personalized medicine : joint EACPT-EPHAR session
Henk Jan Guchelaar:  Clinical implementation of pharmacogenetics
Viktor Hlavac:  Pharmacogenetics of cancer chemoresistance
Seppo Ylä-Herttuala:  Cardiovascular gene therapy
Martina Schusler-Lenz:  Advanced therapy regulation in the EU

Interprofessional working
Ann Lykkegaard Sørensen:  Interprofessional approach for safer medication in psychiatry
Hanna Seidling:  Benchmarks for successful interdisciplinary collaboration

Debate: Deprescribing is Dangerous
Jamie Coleman:  For; Wade Thompson : Against

Targeting small populations
Caridad Pontes:  barriers to market access, 
Violeta Stoyanova:  drug designation and other regulatory challenges

Critically ill patients
Dario Cattaneo:  Anti-infectives in intensive care
Philippe Vignon:  New sepsis drugs in the pipeline: any reason for hope?
Christoph Stein:  New concepts in opioid analgesia

Antibiotic drug resistance
Johan Mouton:  Antimicrobial resistance. Could PK/PD be the answer?
Alexandra Aubry:  New treatment options for resistent tuberculosis

Polypharmacy: joint session with the Korean Society
Howard Lee:  Polypharmacy in Korea
Ho Sook Kim:  The clinical pharmacology perspectives for the optimal polypharmacy in Korea
Kees Kramers:  Polypharmacy: Acting on the cutting edge of safety, efficacy and compliance

Patient empowerment
Bettina Ryll:  Patient empowerment: Issues with introduction of a new class of drugs
Ann Langius Eklöf:  Smart phones provide smart patients

2020 drug strategy
Jordi Llinares:  achievements and future initiatives; Drug regulation in the 2020s:  Gonzalo Calvo: an academic perspective; Graziella Collu: a pharmaceutical industry perspective

Decision support
Matthew Doogue:  Alert, clinical decision support helping patients and hindering work flow
Lars L Gustafsson:  Clinical pharmacologists with computers - the way forward

Friday, 5 April 2019

Updates on the EACPT from Athens


Parthenon, Athens
The EACPT Executive Committee is meeting in Athens from 5th – 6th April 2019 to plan for future activities of the EACPT.

Main topics for discussion include
-       final details for the upcoming 2019 EACPT Congress to be held in Stockholm from 29th June - 2nd July in 2019
-       early planning for the next EACPT Congress, to be held in Athens in 2021, from 26th – 29th June
-       updates from EACPT Research, Regulatory and Education working groups
-       EACPT awards
The next EACPT Congress will be held from 29th June to 2nd July in 2019 in Stockholm as a partnership between the EACPT and the Swedish Society for Pharmacology, Clinical Pharmacology and Therapeutics. 

Early bird registration deadline - 10th April 2019.  Register online for the 2019 EACPT Congress in Stockholm

The Congress will address Tomorrow's Healthcare Challenges and will be held at the City Conference Centre - 5 minutes from Stockholm Central Station.
EACPT committee in Athens by Hippocrates statue. 
Back row: Per Ankaer, MCI (Denmark), Pierre Marquet (France), Vangelis Manolopoulos (Greece), Markus Zeitlinger (Austria), Janne Backman (Finland), Caroline Samer (Switzerland)  Donald Singer (UK),  Michial van Agtmael (Netherlands), Achim Schmidtko (Germany). Front row:  Jamie Coleman (UK), Tabassome Simon (France), Ylva Böttiger (Sweden), Arantxa Sancho Lopez (Spain), Gerard Rongen (Netherlands).
The Congress Reception on the evening of Saturday 29th June, will be held at Stockholm City Hall, the venue of the Nobel Prize banquet.

The Keynote Opening Lecture will be given by the President at the Karolinska Institute, Professor Ole Petter Ottersen, on global health and clinical pharmacology.


Further awards will be presented, including Scientific Awards, including Young Investigator, and EACPT Education Awards.

Around 60 invited speakers are expected from throughout Europe and beyond. Congress keynote lectures, sessions and themes will include:
  • Advanced therapies
  • Ageing populations
  • Anti-coagulation
  • Anti-microbial resistance
  • Beating cancer
  • Chronic disease
  • Clinical drug research of tomorrow
  • Clinical pharmacologists versus computers
  • Clinical use of pharmacokinetics
  • Closing the money gap  
  • Computers vs. clinical pharmacologists
  • Deprescribing
  • Drug-drug interaction
  • Drug regulation in the 2020s
  • Drug utilisation
  • EACPT meets Asian Societies      
  • Ethics in clinical research
  • Global Health
  • How to become a clinical pharmacologist
  • How to make an oral presentation
  • How to measure drug exposure
  • How to measure drug use
  • How to perform a health economic study
  • Inter-professional exchange for better drug treatment
  • Mental health
  • Misuse of medicines
  • Patient empowerment
  • Polypharmacy: joint symposium with the Korean Society (KSCPT)
  •  medicine: EPHAR-EACPT joint symposium
  • Preparing tomorrow's prescribers
  • Prescribing and deprescribing
  • Publish or perish
  • Rare diseases
  • Targeting small populations  
  • The critically ill patient
  • Treating ageing populations 
  • Treating disease in children
Major awards to be presented at the Stockholm Congress include the EACPT Lifetime Achievement Award, the biennial EACPT Scientific Award for best publication on a clinical pharmacology or therapeutic theme, Young Investigator awards jointly with EPHAR, and the EACPT Education Award.

Opportunities for EACPT Associate Members include
* discounted registration fees for EACPT meetings
* networking with colleagues worldwide through the global EACPT network of Associate Members
* active involvement in EACPT Working Parties and other activities 
Future EACPT Congresses will be held in:
- 2021 Athens
- 2023 Rotterdam

The EACPT was founded in 1993 and now includes as members all national organisations for clinical pharmacology in Europe, as well as organisations from further afield internationally. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

Saturday, 9 March 2019

2019 EACPT Lifetime Achievement Award to go to Professor Urs Meyer from Switzerland

The EACPT is delighted to announce that the 2019 Lifetime Achievement Award of the European Association of Clinical Pharmacology and Therapeutics will go to Professor Urs Meyer from Switzerland.

The Award, which includes the EACPT silver medal, will be presented to Professor Meyer during the 2019 EACPT congress in Stockholm which is being held from 29 June to 2 July 2019.
To register for the congress and attend Professor Meyer's Lifetime Award Lecture click on eacpt2019.org 

Urs A. Meyer went through a remarkable career as physician and scientist whose discoveries and scientific results have fundamentally contributed to clinical pharmacology and its development in recent decades.

His research has focused on “pharmacological individuality” or person-to-person variation of drug response throughout his career, from studying the drug sensitivity of the pharmacogenetic disease porphyria to the pharmacogenomics of drug disposition and its co-regulation by drug interactions and environmental factors. 

These predictable variations in drug response are important components of individualized drug therapy or personalized and stratified medicine. Urs Meyer probably is best known for the discovery of the molecular mechanisms of several common genetic polymorphisms of drug disposition. His laboratory identified the genes and mutations in these genes causing variation in drug response and developed the first pharmacogenetic DNA tests, initially for the genes now called CYP2D6 and NAT2. The publications describing these genetic variations in drug response in Nature, PNAS, Lancet, etc. are some of the most cited papers in the therapeutic literature. 

At that time they transformed the field of pharmacogenetics into a molecular science. Urs Meyer’s group was engaged and productive in a further type of inter-individual variation of drug response, namely the transcriptional activation or repression of numerous genes, including many drug metabolizing enzymes and drug transporters, by exogenous and endogenous factors. His laboratory has discovered important early steps in the recognition mechanisms for these factors in cells and the consequent signal transfer to the nucleus.  This is an area of great clinical importance with regard to understanding inter-individual variations in the therapeutic and toxic effects of drugs. 

Urs Meyer takes care of most of the porphyria families in Switzerland and in several surrounding countries. Focusing on the pharmacogenetic disease porphyria and its unsolved syndrome of neuropsychiatric symptoms Urs Meyer’s team has developed an animal model of this pharmacogenetic disease, imitating the human defect. These mice have a phenotype closely resembling the human disorder and are presently used in several laboratories to develop new therapeutic approaches to the treatment of inducible acute porphyria.

Sustained productivity across the domains of basic and clinical pharmacology has resulted in over 340 original publications, reviews and book chapters. Urs Meyer has been listed since 2001 within the exclusive ISI’s Highly Cited Researchers database. His publications have been cited over 30,000 times and his H-index is 93. Urs Meyer’s scientific achievements have also has been recognized by numerous awards and honours, including the Rawls-Palmer Award for Progress in Medicine of the American Society for Clinical Pharmacology and Therapeutics and the RT Williams Distinguished Scientific Achievement Award of the International Society for the Study of Xenobiotics – among many others.

Beyond the laboratory and patient care, Urs Meyer has maintained a strong commitment to the teaching of rational therapeutics to medical students and to training programmes in drug development sciences, e.g. within the European Center for Pharmaceutical Medicine ECPM courses in science-based drug development. He has trained 71 graduate students and 62 post-doctoral fellows and more than 35 of his previous collaborators are now in academic positions all over the world. A number of scientists, of whom 9 from the USA, have spent time as sabbatical professors in the laboratory of Urs Meyer.

Urs Meyer also has assumed leadership roles at the international level, including the WHO and NIH. He has served on numerous peer review panels and editorial boards, presently as Associate Editor of Annual Reviews of Pharmacology and Toxicology. He was the inaugural Editor-in-Chief of the Journal of Personalized Medicine in 2011. As an example of his international activities, he was selected to present the Pharmacogenomics Research Network PGRN to the NIH Council in 2000 and was a member of the External Scientific Panel for this program. He also was president of the International Society for the Study of Xenobiotics (ISSX) 2010-2011, with offices in Washington, D.C.

The EACPT was founded 25 years ago and now includes as members all national organisations for clinical pharmacology in Europe, as well as organisations from further afield internationally. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

The official journal of the EACPT is the European Journal of Clinical Pharmacology

Monday, 11 February 2019

Still time to submit an abstract for the EACPT Congress in Sweden: 29th June to 2nd July 2019

Stockholm
The next EACPT Congress will be held from 29th June to 2nd July in 2019 in Stockholm as a partnership between the EACPT and the Swedish Society for Pharmacology, Clinical Pharmacology and Therapeutics.

The Congress will address Tomorrow's Healthcare Challenges and will be held at the City Conference Centre - 5 minutes from Stockholm Central Station.


Abstract closing date extended to 14th March.


The Congress Reception on the evening of Saturday 29th June, will be held at Stockholm City Hall, the venue of the Nobel Prize banquet.

The Keynote Opening Lecture will be given by the President at the Karolinska Institute, Professor Ole Petter Ottersen, on global health and clinical pharmacology.

Around 60 invited speakers are expected from throughout Europe and beyond. Congress keynote lectures, sessions and themes will include:
  • Advanced therapies
  • Chronic disease
  • Clinical pharmacologists versus computers
  • Closing the money gap  
  • Drug regulation in the 2020's
  • EACPT meets Asian Societies      
  • EPHAR-EACPT joint symposium on personalised medicine
  • Ethics in clinical research
  • Global Health
  • How to become a clinical pharmacologist
  • How to measure drug exposure
  • How to measure drug use
  • How to perform a health economic study
  • Interprofessional exchange for better drug treatment
  • Misuse of medicines
  • Patient empowerment
  • Preparing tomorrow's prescribers
  • Prescribing and deprescribing
  • Targeting small populations  
  • The critically ill patient
  • Treating ageing populations 
  • Treating cancer
  • Treating children
Major awards to be presented at the Stockholm Congress include the EACPT Lifetime Achievement Award and the biennial EACPT Scientific Award for best publication on a clinical pharmacology or therapeutic theme.

Opportunities for EACPT Associate Members include
* discounted registration fees for EACPT meetings
* networking with colleagues worldwide through the global EACPT network of Associate Members
* active involvement in EACPT Working Parties and other activities 
Future EACPT Congresses will be held in:
- 2021 Athens
- 2023 Rotterdam

The EACPT was founded in 1993 and now includes as members all national organisations for clinical pharmacology in Europe, as well as organisations from further afield internationally. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

Thursday, 6 September 2018

Updates on the EACPT from the UK


The EACPT Executive Committee is meeting in early September 2018 in Birmingham in the UK West Midlands to plan for future activities. This coincides with the latest EACPT Focus meeting: Innovations in CPT Education - which is being held at the University of Birmingham from 7-8 September 2018. Delegates for the Focus meeting are expected from a wide range of countries, including Finland, Germany, Ireland, The Netherlands, Sweden, Switzerland, Lithuania, Poland, Italy, Spain, Romania, Malta and the UK.

EACPT EC in Birmingham
Key matters for discussion by the EACPT EC included:
1. Future EACPT Congresses - the next is due to be held from 29th June to 2nd July in 2019 in Stockholm as a partnership between the EACPT and the Swedish Society for Pharmacology, Clinical Pharmacology and Therapeutics. The Congress will address Tomorrow's Healthcare Challenges and will be held at the City Conference Centre - 5 minutes from Stockholm Central Station.
The Keynote Opening Lecture will be given by the President at the Karolinska Institute, Professor Ole Petter Ottersen, on global health and clinical pharmacology.

Congress sessions and themes will include:
  • Advanced therapies
  • Chronic disease
  • Clinical pharmacologists versus computers
  • Closing the money gap  
  • Drug regulation in the 2020's
  • EACPT meets Asian Societies      
  • EPHAR-EACPT joint symposium on personalised medicine
  • Ethics in clinical research
  • Global Health
  • How to become a clinical pharmacologist
  • How to measure drug exposure
  • How to measure drug use
  • How to perform a health economic study
  • Interprofessional exchange for better drug treatment
  • Misuse of medicines
  • Patient empowerment
  • Preparing tomorrow's prescribers
  • Prescribing and deprescribing
  • Targeting small populations  
  • The critically ill patient
  • Treating ageing populations 
  • Treating cancer
  • Treating children
2. New EACPT Awards for Best Scientific Paper in the previous 12 months on a clinical pharmacology or therapeutics theme. Authors may be from any discipline and do not have to be members of the EACPT. These awards will be launched in September 2018 and awarded initially every 2 months (6 times a year) from November 2018. 

Award winners will receive a free one year Individual Associate Membership (IAM) of the EACPT. Winners who are already EACPT IAMs will receive a 100€ prize. Papers which receive an EACPT Scientific Paper Award will be eligible to be considered for the biennial EACPT Scientific Award.

3. EACPT working groups on Education, Research, Young Professionals, and Regulation and Ethics.

4. New EACPT web series on Meet the Clinical Pharmacologists

5. Opportunities from links with international organisations such as the European Medicines Agency, IUPHAR, EPHAR and UEM|

6. Opportunities for Individual Associate Members including:
* discounted registration fees for EACPT meetings
* networking with colleagues worldwide through the global EACPT network of Associate Members
* active involvement in EACPT Working Parties and other activities  
The EACPT Executive Committee meets 6 monthly, with regular additional discussions by teleconference on key EACPT strategy and activities.
Future EACPT Congresses will be held in:
- 2019 Stockholm
- 2021 Athens
- 2023 Rotterdam

The EACPT was founded in 1993 - 25 years ago - and now includes as members all national organisations for clinical pharmacology in Europe, as well as organisations from further afield internationally. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

Tuesday, 17 April 2018

Updates on digital media and health at the European Medicines Agency


Safe and effective healthcare matters for society as a whole.

Digital media and health is the key theme of the latest joint meeting of the European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) being held in London on 17th and 18th April 2018. Digital media and health topics are being discussed, including recent learning and trends with regard to mHealth, social media, real-word evidence and electronic product information.

Katja Neubauer from the European Commission opened the session with an update on EU initiatives with regard to digital health. She considered 3 priority areas on digitizing health and care: access of the citizen to his or her data for example in electronic medical records and electronic prescribing; access to big data to improve health policy and regulatory decisions; and using digital health make policy decisions more patient-centred.
She discussed clinical use studies, including development of European Reference rare diseases, applying digital health to anticipating epidemics and EU-wide infectious threats and applying Real World Data in medicines development.

An EC report on Digital Single Market strategy is due to be published on 25th April.
Hans-Georg Eichler from the EMA went on to discuss the relevance of real world evidence to regulation of medicines, including understanding efficacy and monitoring for unexpected risk and for long-term risk. In particular, he considered use of real world evidence to match the speed of science progress with timely integration of innovations into clinical practice.
He considered case studies on accelerating drug development, contrasting findings from real world evidence with those from classical randomized clinical trials; applying real world evidence to monitoring potential long term adverse effects of medicines – for example from risks of insertional mutagenesis following gene therapy for thalassaemia which needs surveillance for decades; and applying real world evidence to understanding therapeutic complexity – for example deciphering combinatorial complexity in oncology treatment with regard to differences in therapeutic impact from treatment order, dose and washout duration between treatments.

He also discussed applying learning for health care from other sectors (aviation, automotive …), including data-driven innovation from rapid feedback loops.
Alison Cave from the EMA discussed key points from recent workshops hosted by the Agency. She stressed the need for a common data model for Europe. A key theme arising from discussion of EMA registries had been the need for common core data elements, checks on data quality (consistency, accuracy and completeness), long-term curation, availability and governance.

Jane Mosely discussed how real-world evidence and patient registries can be used to support early access to medicines, risk-benefit analysis and provide rapid replication within different populations of initial findings. She noted that there are currently limited requests for data from real-world evidence to support pre-authorisation decisions and post-authorisation questions about safety and efficacy. Some aspects which need to be considered include eligibility of participants, outcome definition, patient safety, and extrapolation of findings throughout the EU
.

Alexios Skarlatos (EMA) and Dr. César Hernández García (Spanish Agency of Medicines and Medical Devices) discussed Electronic Product Information. Steps include consultation on revising Patient Leaflet content and adding agreed new content, including targeted messages for relevant subgroups of patients. There are already case studies from the Netherlands (Watchyourmeds), quick guides for patients in Norway and in Spain structured product information accessible e.g. by scanned quick response (QR) codes. International standards are needed and transition to a Digital first model.  There will be a European Commission-EMA-HMA multistakeholder workshop on the use of electronic Summary of medical Product Characteristics (SmPC)/Patient Leaflets (PL) on 28th – 29th November 2018.

Further speakers will discuss from health professional, regulator, patient, consumer perspectives Real World Evidence (Kieran Breen, Patient Representative on the EMA Committee for Advanced Therapies), mHealth (Kathi Apostolidis, European Cancer Patient Coalition) and Social Media (Caroline Morton, International Bureau for Epilepsy).
More about the meeting and the presentations can be found on the EMA website.